Taxane-induced scleroderma.
Report of two cases

JADE CURY-MARTINS¹, LAURA GIESEN², SERGIO GONZÁLEZ³, MONTSERRAT MOLGO², JOSE ANTONIO SANCHES¹,a

ABSTRACT

Taxanes are a class of chemotherapeutic agents with common associated dermatologic adverse events, such as skin hyperpigmentation, hand-foot skin syndrome, paronychia and onycholysis. Taxane-induced scleroderma is rare. Few cases with skin findings resembling systemic sclerosis, have been reported after the administration of these agents. We report two cases with stage IV breast cancer, aged 66 and 71 years, who developed sclerodermic skin lesions in their extremities after starting treatment with placticel and nabplacticel respectively.

(Rev Med Chile 2021; 149: 807-809)

Key words: Drug Related Side Effects and Adverse Reactions; Scleroderma, Localized; Taxoids; Antineoplastic Agents.

Esclerodermia inducida por taxanos.
Informe de dos casos

Los taxanos son agentes quimioterapéuticos cuyo uso se asocia a problemas dermatológicos tales como hiperpigmentación, síndrome manos-pies, paroniquia y onicólisis. La esclerodermia inducida por taxanos es rara, con pocos casos informados en la literatura. Informamos los casos de dos pacientes con cáncer de mama en estado IV, de 66 y 71 años, que desarrollaron lesiones escleródérmicas en las extremidades después de ser tratadas con placticel y nabplacticel, respectivamente.

Palabras clave: Antineoplásicos; Efectos Colaterales y Reacciones Adversas Relacionadas con Medicamentos; Esclerodermia Localizada; Taxoides.

Case reports

A 66-year-old male with stage IV breast carcinoma was treated with neoadjuvant tamoxifen, followed by letrozole and radiotherapy with progressive disease after 2 years. He was then initiated on paclitaxel. Four months later he started to develop edema on the extremities, evolving to skin induration/thickening with a distal to proximal progression (Figure 1 A-B). Histology revealed dermal fibrosis with thickened collagen bundles
and scarce inflammatory infiltrate without mucin deposition (Figure 1 C). Laboratory investigations were negative for antinuclear antibody (ANA), anti-Scl-70 and rheumatoid factor; protein electrophoresis, complement levels, thyroid stimulating hormone (TSH) were within normal range. X-ray of the esophagus and nail fold capillaroscopy were normal and thorax computed tomography revealed no alterations suggestive of systemic sclerosis. Phototherapy (PUVA) was planned, but patient died before starting skin-directed treatment due to disease progression.

Second case is of a 71-year-old female with stage IV breast carcinoma who started treatment in a clinical trial with Nabpaclitaxel +/- Atezolizumab/placebo. Shortly after treatment initiation, patient developed edema on the left distal arm, evolving 4 months later with limbs dysesthesias and skin hyperpigmentation, followed by skin induration/thickening of the extremities with a distal to proximal progression (Figure 2 A-B). Histology revealed dermal fibrosis with thickened collagen bundles, discrete adnexal atrophy, presence of dendrocytes and absence of inflammatory infiltrate, fibroblasts and mucin deposition (Figure 2 D). Laboratory findings were only positive for a low titer anti-Ro and were negative for ANA, Anti-RNP/Sm, Sm, La, Scl-70, Jo-1. TSH levels and renal function were normal. Due to disease progression, protocol was suspended and capecitabine was started with good response and improvement of skin sclerosis (Figure 2 C).
Discussion

Taxanes are a group of chemotherapeutic agents widely used to treat solid tumors such as ovarian, breast, lung, among others. The two main representatives are docetaxel and paclitaxel. Nab-paclitaxel is an albumin-bound paclitaxel. The main related dermatological adverse events are skin hyperpigmentation, hand-foot skin syndrome, paronychia and onycholysis.

Taxane-induced scleroderma is a rare event, with approximately 25 cases reported in the literature, most of them related to paclitaxel. Even though many patients had received other chemotherapy agents, a time correlation is suggestive of taxanes as the causative agent. Lesions start from weeks to several months after drug initiation (most cases around 3-6 months), usually with edema on the extremities, evolving to skin tightening and sclerosis, with a distal to proximal progression. There is no relationship with a specific type of tumor, with cases of breast, ovarian, endometrium and peritoneum being described.

Differently from classic systemic sclerosis (SSc), ANA antibodies are negative or, less often, positive with no specific SSc pattern; vascular phenomenon such as Raynaud or nail fold changes are usually absent, and no esophagus or pulmonary involvement is usually detected.

Mechanisms are still poorly understood, but it is believed they are mainly induced by a toxic and non-immunomediated mechanism. They are usually dose-dependent, and dose reductions or even discontinuation of the taxane is sometimes necessary. Other treatments reported are corticosteroids (topical or systemic), PUVA and methotrexate, with variable responses.

Conclusion

Even though rare, taxane-induced scleroderma might cause important morbidity. It is important for dermatologists and oncologists to be aware of this possible association, since early identification and management are critical for maintaining quality of life in cancer patients.

References

1. Kupper I, Balguerie X, Courville P, Chinet P, Joly P. Scleroderma-like cutaneous lesions induced by paclitaxel: a case study. J Am Acad Dermatol. 2003; 48 (2): 279-81.
2. Shibao K, Okiyama N, Maruyama H, Jun-Ichi F, Fujimoto M. Scleroderma-like skin changes occurring after the use of paclitaxel without any chemical solvents: a first case report. Eur J Dermatol. 2016; 26 (3): 317-8.
3. Pedersen JV, Jensen S, Krarup-Hansen A, Riis L. Scleroderma induced by paclitaxel. Acta Oncol. 2010; 49 (6): 866-8.
4. Itoh M, Yanaba K, Kobayashi T, Nakagawa H. Taxane-induced scleroderma. Br J Dermatol. 2007; 156 (2): 363-7.
5. Konishi Y, Sato H, Sato N, Fujimoto T, Fukuda J, Tanaka T. Scleroderma-like cutaneous lesions induced by paclitaxel and carboplatin for ovarian carcinoma, not a single course of carboplatin, but re-induced and worsened by previously administrated paclitaxel. J Obstet Gynaecol Res. 2010; 36 (3): 693-6.
6. Verhulst L, Noë E, Morren MA, Verlype C, van Cutsen E, van der Oord J, der Haes P. Scleroderma-like cutaneous lesions during treatment with paclitaxel and gemcitabine in a patient with pancreatic adenocarcinoma. Review of literature. Int J Dermatol. 2018; 57 (9): 1075-9.